BACKGROUND: Plasmablastic lymphoma has recently come to be considered a distinct entity among mature B cell neoplasms, although the limits with diffuse large B-cell lymphoma (DLBCL) need to be more accurately defined. DESIGN AND METHODS: Here we show the results of an immunohistochemical study of 35 cases of plasmablastic lymphoma compared with a set of 111 conventional DLBCLs. RESULTS: Our results demonstrate that the use of a limited combination of immunohistochemical markers (PAX5&CD20, PRDM1/BLIMP1 and XBP1s) enables the identification of a plasmablastic immunophenotype highly characteristic of plasmablastic lymphoma cases and associated with an aggressive clinical behavior. Additionally, the study shows that the acquisition of a partial plasmablastic phenotype (PRDM1/BLIMP1 expression) in DLBCL is associated with shorter survival in R-CHOP-treated patients. CONCLUSIONS: The use of a restricted combination of immunohistochemical markers (PAX5&CD20, PRDM1/BLIMP1 and XBP1s) enables a more accurate definition of terminal differentiation for large B-cell lymphoma.
BACKGROUND:Plasmablastic lymphoma has recently come to be considered a distinct entity among mature B cell neoplasms, although the limits with diffuse large B-cell lymphoma (DLBCL) need to be more accurately defined. DESIGN AND METHODS: Here we show the results of an immunohistochemical study of 35 cases of plasmablastic lymphoma compared with a set of 111 conventional DLBCLs. RESULTS: Our results demonstrate that the use of a limited combination of immunohistochemical markers (PAX5&CD20, PRDM1/BLIMP1 and XBP1s) enables the identification of a plasmablastic immunophenotype highly characteristic of plasmablastic lymphoma cases and associated with an aggressive clinical behavior. Additionally, the study shows that the acquisition of a partial plasmablastic phenotype (PRDM1/BLIMP1 expression) in DLBCL is associated with shorter survival in R-CHOP-treated patients. CONCLUSIONS: The use of a restricted combination of immunohistochemical markers (PAX5&CD20, PRDM1/BLIMP1 and XBP1s) enables a more accurate definition of terminal differentiation for large B-cell lymphoma.
Authors: I Simonitsch-Klupp; I Hauser; G Ott; J Drach; J Ackermann; J Kaufmann; A Weltermann; H T Greinix; C Skrabs; C Dittrich; D Lutz; R Pötter; C Mannhalter; K Lechner; A Chott; U Jaeger Journal: Leukemia Date: 2004-01 Impact factor: 11.528
Authors: Lisa M Rimsza; Robin A Roberts; Thomas P Miller; Joseph M Unger; Michael LeBlanc; Rita M Braziel; Dennis D Weisenberger; Wing C Chan; H Konrad Muller-Hermelink; Elaine S Jaffe; Randy D Gascoyne; Elias Campo; Deborah A Fuchs; Catherine M Spier; Richard I Fisher; Jan Delabie; Andreas Rosenwald; Louis M Staudt; Thomas M Grogan Journal: Blood Date: 2004-02-19 Impact factor: 22.113
Authors: Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan Journal: Blood Date: 2003-09-22 Impact factor: 22.113
Authors: William W L Choi; Dennis D Weisenburger; Timothy C Greiner; Miguel A Piris; Alison H Banham; Jan Delabie; Rita M Braziel; Huimin Geng; Javeed Iqbal; Georg Lenz; Julie M Vose; Christine P Hans; Kai Fu; Lynette M Smith; Min Li; Zhongfeng Liu; Randy D Gascoyne; Andreas Rosenwald; German Ott; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; David L Jaye; Louis M Staudt; Wing C Chan Journal: Clin Cancer Res Date: 2009-08-25 Impact factor: 12.531
Authors: Juan F García; Francisca I Camacho; Manuel Morente; Máximo Fraga; Carlos Montalbán; Tomás Alvaro; Carmen Bellas; Angel Castaño; Ana Díez; Teresa Flores; Carmen Martin; Miguel A Martinez; Francisco Mazorra; Javier Menárguez; Maria J Mestre; Manuela Mollejo; Ana I Sáez; Lydia Sánchez; Miguel A Piris Journal: Blood Date: 2002-09-12 Impact factor: 22.113
Authors: Sarah T Wilkinson; Kristie A Vanpatten; Diane R Fernandez; Patrick Brunhoeber; Karl E Garsha; Betty J Glinsmann-Gibson; Thomas M Grogan; Julie Teruya-Feldstein; Lisa M Rimsza Journal: Blood Date: 2011-12-13 Impact factor: 22.113
Authors: Monika Schmelz; Santiago Montes-Moreno; Miguel Piris; Sarah T Wilkinson; Lisa M Rimsza Journal: Haematologica Date: 2012-06-11 Impact factor: 9.941
Authors: Carlo Visco; Sylvia Hoeller; Jeffrey T Malik; Zijun Y Xu-Monette; Michele L Wiggins; Jessica Liu; Warren G Sanger; Zhongfeng Liu; Julie Chang; Erik A Ranheim; Joel F Gradowski; Sergio Serrano; Huan-You Wang; Qingquan Liu; Sandeep Dave; Brian Olsen; Randy D Gascoyne; Elias Campo; Steven H Swerdlow; Wing C Chan; Alexander Tzankov; Ken H Young Journal: Am J Surg Pathol Date: 2011-02 Impact factor: 6.394
Authors: J Chapman; A J Gentles; V Sujoy; F Vega; C I Dumur; T L Blevins; L Bernal-Mizrachi; M Mosunjac; A Pimentel; D Zhu; I S Lossos Journal: Leukemia Date: 2015-04-24 Impact factor: 11.528
Authors: Santiago Montes-Moreno; Nerea Martinez-Magunacelaya; Tomás Zecchini-Barrese; Sonia Gonzalez de Villambrosía; Emma Linares; Tamara Ranchal; María Rodriguez-Pinilla; Ana Batlle; Laura Cereceda-Company; Jose Bernardo Revert-Arce; Carmen Almaraz; Miguel A Piris Journal: Mod Pathol Date: 2016-09-30 Impact factor: 7.842
Authors: Y Xia; Z Y Xu-Monette; A Tzankov; X Li; G C Manyam; V Murty; G Bhagat; S Zhang; L Pasqualucci; C Visco; K Dybkaer; A Chiu; A Orazi; Y Zu; K L Richards; E D Hsi; W W L Choi; J H van Krieken; J Huh; M Ponzoni; A J M Ferreri; M B Møller; B M Parsons; J N Winter; M A Piris; J Westin; N Fowler; R N Miranda; C Y Ok; Y Li; J Li; L J Medeiros; K H Young Journal: Leukemia Date: 2016-08-29 Impact factor: 11.528